Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations

Slide: 1 of 23

Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Pediatric Populations

This slide set is based on a comparative effectiveness review (CER) titled Antinuclear Antibody, Rheumatoid Factor, and Cyclic-Citrullinated Peptide Testing for the Evaluation of Musculoskeletal Complaints in Children, which was developed by the University of Alberta Evidence-based Practice Center for the Agency for Healthcare Research and Quality (AHRQ) under Contract No. HHSA 290-2007-10021-I and is available online at www.effectivehealthcare.ahrq.gov/anatest.cfm.

In response to a request from the public, a systematic review assessed the diagnostic performance of antinuclear antibody (ANA), rheumatoid factor (RF), and cyclic-citrullinated peptide (CCP) antibody tests in children and adolescents with undiagnosed musculoskeletal (MSK) pain or joint swelling for pediatric systemic lupus erythematosus (pSLE) and juvenile idiopathic arthritis (JIA). The review also characterized the prevalence of MSK pain in children. The systematic review included 28 clinical studies published from January 1960 to January 2010. The full report, listing all studies, is available at www.effectivehealthcare.ahrq.gov/anatest.cfm. This CME activity, based on the full report of research evidence, is provided to inform discussions of options with patients and to assist in decisionmaking along with consideration of a patient’s values and preferences. However, reviews of evidence should not be construed to represent clinical recommendations or guidelines.